Olga Meiri Chaim, Scientist and Associate Professor in Cell Biology at Universidade Federal do Paraná shared a post on LinkedIn:
“Important discussions on myeloid diseases, leukemia above 70 yo and transplants.
On tp53 trial on correlations that are or not exclusions for definition of treatment decisions. Biallelic monoallelic assessment epigenetic silencing blasts. Imagine when they start considering pharmaceutical attention and nutritional concerns for recovery.
Testing imprinting to determine routines.”
Other articles about TP53 on OncoDaily.